Interventional × Thyroid Neoplasms × CNS × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT04284774 2025-12-04

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
155 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled
NCT06673329 2025-05-14

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled
NCT05131815 2025-02-26

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Cedars-Sinai Medical Center

Phase NA Completed
8 enrolled
NCT06787807 2025-01-22

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Universidade Federal de Pernambuco

Phase NA Not yet recruiting
103 enrolled
NCT01624220 2023-12-05

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

M.D. Anderson Cancer Center

Phase NA Completed
41 enrolled
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

SWOG Cancer Research Network

Phase 1 Withdrawn
NCT00581815 2015-12-28

Spectroscopy With Surface Coils and Decoupling

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
582 enrolled
NCT00019331 2013-06-20

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
NCT00098943 2012-09-24

NGR-TNF in Treating Patients With Advanced Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
70 enrolled